Q-omics provides the consensus-scored IDI1 profile across patient tissues and cancer cell-line models. IDI1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, IDI1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, IDI1 protein abundance shows 22,862 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CESC, KIRC, and GBM as cancer lineages where IDI1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IDI1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IDI1 survival associations across molecular data types. IDI1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IDI1 RNA expression–survival associations across cancer types. High IDI1 expression shows unfavorable associations in CESC, ACC, BLCA and THCA, but favorable associations in KIRC and LGG. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for IDI1 RNA expression.
This table summarizes IDI1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IDI1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IDI1 shows lower tumor expression in KIRC, KICH, THCA, KIRP and LUAD and higher tumor expression in LIHC. The KIRC box plot shows higher IDI1 RNA expression in normal versus tumor tissue (log2 FC = −0.958, t-test p < 0.001).
This table shows molecular features associated with IDI1 in patient tissues and cancer cell lines. In patient samples, IDI1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, IDI1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
